This symposium brings together world-leading experts in cancer research and translational medicine to showcase how nanopore sequencing technology is being utilized to identify novel disease biomarkers.

From the characterization of small biomarkers, like circulating tumor DNA and single-nucleotide variants, to large structural variants and base modifications, nanopore sequencing delivers comprehensive insights into the cancer genome.

The speakers will discuss targeted and genome-wide detection of circulating tumor DNA, exploration of brain tumors and sarcomas and how nanopore sequencing has advanced their research.